133 related articles for article (PubMed ID: 37259771)
1. 6-Mercaptopurine potently inhibits recruitment of SHP2 by phosphorylated PD-1 to inhibit PD-1 signalling and enhance T cell function.
Liu L; Lei Y; Zheng Z; Zhou X; Chen S; Zeng G; Yu L; Wang P; Chen L
Immunology; 2023 Oct; 170(2):230-242. PubMed ID: 37259771
[TBL] [Abstract][Full Text] [Related]
2. Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors.
Fan Z; Tian Y; Chen Z; Liu L; Zhou Q; He J; Coleman J; Dong C; Li N; Huang J; Xu C; Zhang Z; Gao S; Zhou P; Ding K; Chen L
EMBO Mol Med; 2020 Jun; 12(6):e11571. PubMed ID: 32391629
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour potential of PD-L1/PD-1 post-translational modifications.
Zhou S; Zhu J; Xu J; Gu B; Zhao Q; Luo C; Gao Z; Chin YE; Cheng X
Immunology; 2022 Dec; 167(4):471-481. PubMed ID: 36065492
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment.
Acúrcio RC; Pozzi S; Carreira B; Pojo M; Gómez-Cebrián N; Casimiro S; Fernandes A; Barateiro A; Farricha V; Brito J; Leandro AP; Salvador JAR; Graça L; Puchades-Carrasco L; Costa L; Satchi-Fainaro R; Guedes RC; Florindo HF
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863821
[TBL] [Abstract][Full Text] [Related]
5. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT; Egbune C
Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
[TBL] [Abstract][Full Text] [Related]
6. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
7. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.
Verdura S; Cuyàs E; Cortada E; Brunet J; Lopez-Bonet E; Martin-Castillo B; Bosch-Barrera J; Encinar JA; Menendez JA
Aging (Albany NY); 2020 Jan; 12(1):8-34. PubMed ID: 31901900
[TBL] [Abstract][Full Text] [Related]
9. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
Li K; Tian H
J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
[TBL] [Abstract][Full Text] [Related]
10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
11. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy.
Liu C; Zhou F; Yan Z; Shen L; Zhang X; He F; Wang H; Lu X; Yu K; Zhao Y; Zhu D
Br J Pharmacol; 2021 Jul; 178(13):2651-2670. PubMed ID: 33768523
[TBL] [Abstract][Full Text] [Related]
13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
14. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
15. Cancer Immunotherapy: An Overview of Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).
Baglini E; Salerno S; Barresi E; Marzo T; Settimo FD; Taliani S
Mini Rev Med Chem; 2022; 22(14):1816-1827. PubMed ID: 35176979
[TBL] [Abstract][Full Text] [Related]
16. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice.
Yassin M; Sadowska Z; Djurhuus D; Nielsen B; Tougaard P; Olsen J; Pedersen AE
Immunology; 2019 Sep; 158(1):35-46. PubMed ID: 31429085
[TBL] [Abstract][Full Text] [Related]
18. Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.
Yuan J; Li J; Shang M; Fu Y; Wang T
Biochem Biophys Res Commun; 2021 Jul; 561():187-194. PubMed ID: 34023785
[TBL] [Abstract][Full Text] [Related]
19. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
20. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]